Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

HER2-positive

25th Feb 2026

DESTINY-CRC02 trial results for trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary

15th Aug 2024

Results from the phase 2b HERIZON-BTC-01 study of zanidatamab in HER2-amplified biliary tract cancer: a plain language summary

This is a summary of the publication about the DESTINY-Gastric01 study, which was published in the New England Journal of Medicine in May 2020. The study included 187 adults in Japan and South Korea with gastric cancer or gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). All the participants’ cancer had spread to nearby or distant parts of the body and had worsened after receiving at least 2 previous cancer treatments or treatment combinations. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than standard chemotherapy drugs.
3rd Nov 2023

A plain language summary of the DESTINY-Gastric01 study: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

25th Nov 2022

Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy